GSK stock: GSK schedules October 28 third-quarter results for investors

Published on 10/23/2026 at 15:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK's dividend yield stands at 4.00 percent. GSK stock costs EUR 22.68 on October 23, 2026 at 3:33 p.m. CEST.

Reporting date October 28, 2026

GSK's third-quarter trading statement is scheduled for October 28, 2026.
GSK's dividend yield stands at 4.00 percent on October 23, 2026.
GSK stock costs EUR 22.68 at Lang & Schwarz on October 23, 2026 at 3:33 p.m. CEST.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK plc is scheduled to publish its third-quarter trading statement on October 28, 2026, according to interactive investor. GSK stock was trading at EUR 22.68 at Lang & Schwarz on October 23, 2026 at 3:33 p.m. CEST.

October 28 sets the next test

The scheduled update is the next fixed date for investors assessing GSK's vaccines, specialty medicines and general medicines. GSK describes its business as focused on developing and manufacturing treatments and vaccines for markets in the United Kingdom, the United States and internationally, according to GSK.

Yield adds income context

GSK's dividend yield stood at 4.00 percent on October 23, 2026. That income figure gives the stock a different profile from a pure growth name, while the October reporting date provides the next scheduled point for reviewing revenue, earnings and guidance.

Healthcare portfolio remains broad

GSK operates across vaccines, HIV, respiratory medicine and oncology. Its investor materials also highlight research and development as a central part of the strategy, making the upcoming trading statement relevant for both established products and pipeline progress.

What comes next

The October 28 release is expected to provide the next dated view of operating performance for the third quarter. For investors, the key comparison will be the company's reported figures with its previous outlook and the market's expectations.